164 related articles for article (PubMed ID: 15542743)
1. Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.
Hasebe K; Kawai K; Suzuki T; Kawamura K; Tanaka T; Narita M; Nagase H; Suzuki T
Ann N Y Acad Sci; 2004 Oct; 1025():404-13. PubMed ID: 15542743
[TBL] [Abstract][Full Text] [Related]
2. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.
Mori T; Nomura M; Nagase H; Narita M; Suzuki T
Psychopharmacology (Berl); 2002 Apr; 161(1):17-22. PubMed ID: 11967626
[TBL] [Abstract][Full Text] [Related]
3. Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.
Takasaki I; Suzuki T; Sasaki A; Nakao K; Hirakata M; Okano K; Tanaka T; Nagase H; Shiraki K; Nojima H; Kuraishi Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):36-41. PubMed ID: 14711930
[TBL] [Abstract][Full Text] [Related]
4. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
Nagase H; Fujii H
Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
Nagase H; Hayakawa J; Kawamura K; Kawai K; Takezawa Y; Matsuura H; Tajima C; Endo T
Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):366-9. PubMed ID: 9501472
[TBL] [Abstract][Full Text] [Related]
6. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats.
Mori T; Nomura M; Yoshizawa K; Nagase H; Narita M; Suzuki T
Life Sci; 2004 Oct; 75(20):2473-82. PubMed ID: 15350822
[TBL] [Abstract][Full Text] [Related]
7. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
8. Modulation of kappa-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats.
Ise Y; Narita M; Nagase H; Suzuki T
Neurosci Lett; 2002 Apr; 323(2):164-6. PubMed ID: 11950518
[TBL] [Abstract][Full Text] [Related]
9. Essential structure of opioid κ receptor agonist nalfurafine for binding to κ receptor 1: synthesis of decahydroisoquinoline derivatives and their pharmacologies.
Nagase H; Imaide S; Yamada T; Hirayama S; Nemoto T; Yamaotsu N; Hirono S; Fujii H
Chem Pharm Bull (Tokyo); 2012; 60(8):945-8. PubMed ID: 22863695
[TBL] [Abstract][Full Text] [Related]
10. Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives.
Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
Bioorg Med Chem Lett; 2017 Aug; 27(16):3920-3924. PubMed ID: 28688957
[TBL] [Abstract][Full Text] [Related]
11. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
[TBL] [Abstract][Full Text] [Related]
12. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.
Tsuji M; Takeda H; Matsumiya T; Nagase H; Narita M; Suzuki T
Life Sci; 2001 Mar; 68(15):1717-25. PubMed ID: 11270618
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Peripheral κ-Opioid Receptor Agonists as Novel Analgesics.
Suzuki S; Sugawara Y; Inada H; Tsuji R; Inoue A; Tanimura R; Shimozono R; Konno M; Ohyama T; Higashi E; Sakai C; Kawai K
Chem Pharm Bull (Tokyo); 2017; 65(11):1085-1088. PubMed ID: 29093296
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists.
Kawai K; Hayakawa J; Miyamoto T; Imamura Y; Yamane S; Wakita H; Fujii H; Kawamura K; Matsuura H; Izumimoto N; Kobayashi R; Endo T; Nagase H
Bioorg Med Chem; 2008 Oct; 16(20):9188-201. PubMed ID: 18829333
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the antinociceptive effects of TRK-820 in the rat.
Endoh T; Tajima A; Suzuki T; Kamei J; Narita M; Tseng L; Nagase H
Eur J Pharmacol; 2000 Jan; 387(2):133-40. PubMed ID: 10650153
[TBL] [Abstract][Full Text] [Related]
16. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
[TBL] [Abstract][Full Text] [Related]
17. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
Yoshikawa S; Hareyama N; Ikeda K; Kurokawa T; Nakajima M; Nakao K; Mochizuki H; Ichinose H
Eur J Pharmacol; 2009 Mar; 606(1-3):102-8. PubMed ID: 19374836
[TBL] [Abstract][Full Text] [Related]
18. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
Nemoto T; Yamamoto N; Wada N; Harada Y; Tomatsu M; Ishihara M; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem Lett; 2013 Jan; 23(1):268-72. PubMed ID: 23200250
[TBL] [Abstract][Full Text] [Related]
19. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
Ko MC; Husbands SM
J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys.
Wakasa Y; Fujiwara A; Umeuchi H; Endoh T; Okano K; Tanaka T; Nagase H
Life Sci; 2004 Oct; 75(24):2947-57. PubMed ID: 15454345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
